SGHT — Sight Sciences, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-07-15.
Performance
Technicals
Others in Healthcare
Measured signals that fired on SGHT
| date | signal | measured base rate |
|---|---|---|
| 2026-04-23 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-04-23 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-10 | Rashid Kashif Chief Legal Officer | Grant or award | 181.8K | 0.00 | 0 |
| 2026-07-06 | HAYDEN JEREMY B. Chief Legal Officer | Open-market sale 10b5-1 plan | 12.7K | 5.51 | 70.1K |
| 2026-07-06 | Badawi David Chief Technology Officer | Open-market sale 10b5-1 plan | 7.4K | 5.51 | 40.9K |
| 2026-07-02 | Bauerlein Alison Chief Operating Officer | Open-market sale 10b5-1 plan | 24.2K | 5.36 | 129.6K |
| 2026-07-02 | Rodberg James Chief Financial Officer | Open-market sale 10b5-1 plan | 6.9K | 5.36 | 37.0K |
| 2026-07-01 | Badawi Paul President and CEO | Open-market sale 10b5-1 plan | 28.7K | 5.42 | 155.5K |
| 2026-07-01 | Taylor Brenton EVP, Operations & R&D | Open-market sale 10b5-1 plan | 2.8K | 5.42 | 15.3K |
| 2026-06-10 | Encrantz Staffan Director | Open-market purchase | 14.1K | 4.88 | 68.8K |
| 2026-06-04 | Encrantz Staffan Director | Grant or award | 28.3K | 0.00 | 0 |
| 2026-06-04 | Burbach Gerhard F Director | Grant or award | 28.3K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Long Focus Capital Management, LLC | 13.5M | 3.6M |
| BlackRock, Inc. | 10.7M | 2.8M |
| Pathstone Holdings, LLC | 9.0M | 2.4M |
| Americana Partners, LLC | 6.3M | 1.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.5M | 1.5M |
| B Group, Inc. | 3.7M | 970.0K |
| GEODE CAPITAL MANAGEMENT, LLC | 3.5M | 915.4K |
| STATE STREET CORP | 3.1M | 835.0K |
| Qube Research & Technologies Ltd | 1.9M | 497.5K |
| DIMENSIONAL FUND ADVISORS LP | 1.3M | 341.7K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 144 | 2026-08-17 | — | on EDGAR ↗ |
| 144 | 2026-08-14 | — | on EDGAR ↗ |
| 144 | 2026-08-13 | — | on EDGAR ↗ |
| 144 | 2026-08-12 | — | on EDGAR ↗ |
| 144 | 2026-08-11 | — | on EDGAR ↗ |
| 8-K | 2026-08-10 | 2026-08-06 | on EDGAR ↗ |
| 10-Q | 2026-08-05 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-05 | 2026-08-05 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Sight Sciences Announces FDA Label Expansion For TearCare Dry Eye Therapy · 2026-08-19
- Sight Sciences, Inc. (SGHT) filed form 144 · 2026-08-17 · SEC EDGAR
- Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript · 2026-08-12
- Sight Sciences, Inc. (SGHT) filed form 8-K · 2026-08-10 · SEC EDGAR
Ask the AI about SGHT
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →